Hillman Solutions Corp shares rise 3.41% intraday after Actuate Therapeutics announced a clinical trial collaboration with UPMC Hillman Cancer Center.

Hillman Solutions Corp. rose 3.41% during intraday trading. The company's stock price increase aligns with the news that Actuate Therapeutics, Inc. has initiated a Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being conducted in collaboration with UPMC Hillman Cancer Center and Incyte Corporation.